论文部分内容阅读
目的探讨特布他林联合布地奈德治疗支气管哮喘的临床疗效及安全性。方法选取德阳市中江县人民医院2015年2月—2016年7月收治的支气管哮喘急性发作患者100例,随机分为对照组和观察组,各50例。对照组患者给予常规治疗,观察组患者在对照组基础上给予特布他林+布地奈德治疗,两组患者均持续治疗7 d。比较两组患者的临床疗效,治疗前后肺功能指标[第1秒用力呼气容积占预计值百分比(FEV1%)、峰值呼气流速占预计值百分比(PEF%)、FEV1占用力肺活量比值(FEV1/FVC)]及不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前,两组患者FEV1%、PEF%及FEV1/FVC比较,差异无统计学意义(P>0.05);治疗后,观察组患者FEV1%、PEF%及FEV1/FVC高于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论特布他林联合布地奈德治疗支气管哮喘的临床疗效确切,可有效改善患者肺功能指标,且安全性好。
Objective To investigate the clinical efficacy and safety of terbutaline combined with budesonide in the treatment of bronchial asthma. Methods One hundred patients with acute exacerbation of bronchial asthma who were treated in Zhongjiang County People’s Hospital of Deyang from February 2015 to July 2016 were randomly divided into control group and observation group, with 50 cases in each group. Patients in the control group were given routine treatment. Patients in the observation group were treated with terbutaline and budesonide on the basis of the control group, and both groups were treated for 7 days. The clinical efficacy of the two groups were compared before and after treatment. The pulmonary function indexes [FEV1%], PEF%, FEV1 (FEV1) / FVC)] and the occurrence of adverse reactions. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). Before treatment, FEV1%, PEF% and FEV1 / FVC had no significant difference between the two groups (P> 0.05). After treatment, FEV1%, PEF% and FEV1 / FVC in the observation group were higher than those in the control group (P < 0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Terbutaline combined with budesonide in the treatment of bronchial asthma clinical curative effect, which can effectively improve patients with lung function indicators, and good safety.